Views & Analysis | Perspectives on pharma industry issues

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Articles

The value of medicine: opportunities, not threats

Even before the clinical trials are designed, a value proposition should be front of mind for healthcare brands. Detailed landscaping and a more proactive approach to value are essential in avoiding the old silk purse / sow’s ear scenario, as Dr Bruce Charlesworth explains….. We’ve all heard similar phrases, but “activities to overcome market access hurdles” sounds very reactive. It’s as though an unpredictable threat…

Articles

The importance of microbiological quality control in the pha...

Microbial contamination in pharmaceutical products has massive consequences. Karla Fjeld explains what we can do to optimise our QC and help prevent contamination. In recent years, the number of major drug recalls within the Pharmaceutical industry has skyrocketed from 426 in 2008 to 1,742 in 2009…

Articles

Oncology drug lag in Japan is improving significantly

The delay between Japan and the West in approving drugs was a considerable problem back in 2006 but recent evidence shows that Japan is catching up and drug lag is in decline in this area. Gordon Gochenauer explains… Nearly every oncology drug in development in Japan is also in development in the United States and Europe, according to the most recent…

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology